With a CAGR of 12.5%, the global pyrogen testing market is expected to witness significant growth during the forecast period. The increasing prevalence of communicable diseases and epidemics are the reasons for the demand for pyrogen testing techniques during the forecast period 2021–2027. The increased investment in research and development activities by manufacturing companies and initiatives by the government for new product development will contribute to the growth of the pyrogen testing market. Nevertheless, the rising number of outsourcing activities in the pharmaceutical sector will provide promising opportunities for the growth of the pyrogen testing market.

Lonza has launched the PyroCell monocyte activation test system to provide reliable and sustainable in vitro pyrogen tests for primary cells and endotoxin tests.

The increased demand for in-vitro assays to identify the presence and concentration of bacterial endotoxins in biological products and drugs will fuel steady growth during the COVID-19 outbreak.

Request to get a free sample copy at https://www.vynzresearch.com/healthcare/pyrogen-testing-market/request-sample

Based upon application, medical device manufacturing is anticipated to witness high CAGR in the pyrogen testing market during 2021–2027 owing to the introduction of technologically developed products and rising demand for high-quality medical devices for therapeutic and diagnostic applications that will fuel the growth of the segment.

North America dominates the pyrogen testing market owing to the prominence of chronic and infectious diseases, well-developed regulatory framework, increasing presence of pharmaceutical companies, and developments in R&D activities.

Some of the major players in the pyrogen testing market include Associates of Cape Cod, Inc., Merck KGaA, Thermo Fisher Scientific, Inc., GenScript, Charles River Laboratories, Inc., Ellab A/S, Lonza Group, and WUXI Pharmatech (Cayman) Inc.

Source VynZ Research